Loading
Ferroptosis and Cancer Prognosis · Journal article
Frontiers in Oncology · August 17, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study evaluated six pretreatment composite inflammatory indices in 280 breast cancer patients treated with neoadjuvant therapy and found associations between lower neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value with pathological complete response; however, discriminatory ability was modest (area under curve 0.67 or lower), limiting clinical utility as standalone predictors.
Retrospective cohort study. 280 patients with breast cancer who underwent neoadjuvant therapy followed by surgery; no additional eligibility criteria stated.. Intervention: Baseline composite inflammatory indices (six calculated from pretreatment blood tests). Compared with: Pathological response status (complete response vs. incomplete response; favorable Miller-Payne vs. other grades). n = 280.
115 of 280 patients (41%) achieved pathological complete response Systemic immune-inflammation index had the highest area under the curve at 0.673 for pathological complete response and 0.666 for favorable Miller-Payne response Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value remained inversely associated with pathological complete response after multivariable adjustment
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These inflammatory indices show associations with pathological response but lack sufficient discriminatory ability to function as standalone clinical predictors. They may have utility as supplementary markers in conjunction with other prognostic factors, but clinical decision-making should not rely on them alone.
A retrospective cohort study demonstrating associations between inflammatory biomarkers and pathological response endpoints, but with modest discriminatory ability and no clear clinical decision threshold.
As stated by the source record.
Quoted from the source exactly as published.
These inflammatory indices show associations with pathological response but lack sufficient discriminatory ability to function as standalone clinical predictors. They may have utility as supplementary markers in conjunction with other prognostic factors, but clinical decision-making should not rely on them alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Pretreatment inflammatory indices may reflect the host immune-inflammatory status in breast cancer. Evidence comparing multiple composite indices across pathological response endpoints after neoadjuvant therapy remains limited. This study evaluated the associations between pretreatment composite inflammatory indices and pathological response in breast cancer. Methods This retrospective study included 280 patients with breast cancer who underwent neoadjuvant therapy followed by surgery. Baseline neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and pan-immune-inflammation value were calculated from pretreatment blood tests. The primary endpoint was pathological complete response, defined as ypT0/is ypN0. Miller-Payne grades 4–5 were defined as favorable pathological response. Logistic regression and receiver operating characteristic analyses were performed. Results A total of 115 patients achieved pathological complete response. Patients with pathological complete response had lower neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value than those without pathological complete response. These indices remained inversely associated with pathological complete response after multivariable adjustment. For favorable Miller-Payne response, lower systemic immune-inflammation index and pan-immune-inflammation value and higher lymphocyte-to-monocyte ratio were associated with better response. Systemic immune-inflammation index had the numerically highest area under the curve, with values of 0.673 for pathological complete response and 0.666 for favorable Miller–Payne response, although its discriminatory ability remained modest. Conclusion Baseline composite inflammatory indices were associated with pathological response to neoadjuvant therapy in breast cancer, but their discriminatory ability was modest. These indices may be more suitable as supplementary markers than as standalone predictors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.